

In the Claims

Please amend the claims as follows. A complete set of pending claims is presented below, with insertions indicated by underlining and deletions indicated by strikethrough.

1.-7. (Canceled)

8. (Previously presented) A method for stimulating an immune response in a HLA-B35 positive subject, comprising:

administering to the subject a MAGE-A1 HLA-B35 binding peptide comprising SEQ ID NO:10 or an agent presenting a complex of a MAGE-A1 HLA-B35 binding peptide comprising SEQ ID NO:10 and a HLA-B35 molecule, in an amount sufficient to stimulate an immune response specific for the MAGE-A1 HLA-B35 binding peptide or the complexes.

9. (Previously presented) The method of claim 8, wherein the agent is an antigen presenting cell which expresses a HLA-B35 molecule contacted with a MAGE-A1 protein or a HLA binding fragment thereof which comprises SEQ ID NO:10.

10.-78. (Canceled)

79. (Previously presented) The method of claim 8 wherein the MAGE-A1 HLA-B35 binding peptide is selected from the group consisting of (i) SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10, and (ii) functional variants of the peptides of (i).

80. (Previously presented) The method of claim 8 wherein the MAGE-A1 HLA-B35 binding peptide is a fragment of SEQ ID NO:2 that comprises SEQ ID NO:10, and (ii) functional variants of the peptides of (i).

81. (Previously presented) The method of claim 8, further comprising administering an immune response potentiating compound.

82. (Previously presented) The method of claim 81, wherein the immune response potentiating compound is an adjuvant.

83. (Previously presented) The method of claim 81, wherein the immune response potentiating compound is a cytokine.

84. (Previously presented) The method of claim 8, wherein the stimulated immune response includes an increase in antibodies or T lymphocytes which are specific for the MAGE-A1 HLA-B35 binding peptide that is administered.

85. (Currently amended) The method of claim 8, further comprising administering to the subject at least one isolated HLA binding peptide selected from the group consisting of (1) MAGE-A1 HLA class I binding peptides other than peptides comprising SEQ ID NO:8, (2) MAGE-A1 HLA class II binding peptides, and (3) ~~MAGE-A1~~ HLA class I or class II binding peptide of a non-MAGE-A1 tumor antigen, in an amount sufficient to stimulate an immune response.